company background image
OSMT

Osmotica PharmaceuticalsNasdaqGS:OSMT Stock Report

Last Price

US$1.13

Market Cap

US$94.1m

7D

-1.7%

1Y

-74.0%

Updated

17 Jan, 2022

Data

Company Financials +
OSMT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

OSMT Stock Overview

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals Competitors

Pfizer

NYSE:PFE

US$308.4b

Novartis

SWX:NOVN

CHF184.2b

Takeda Pharmaceutical

TSE:4502

JP¥5.3t

Price History & Performance

Summary of all time highs, changes and price drops for Osmotica Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.13
52 Week HighUS$4.95
52 Week LowUS$0.98
Beta1.96
1 Month Change14.84%
3 Month Change-41.75%
1 Year Change-74.02%
3 Year Change-86.22%
5 Year Changen/a
Change since IPO-86.13%

Recent News & Updates

Dec 14

Osmotica: A Different Breed Of Cat

Having closed on the sale of its legacy business, Osmotica had UPNEEQ, arbaclofen ER, and little else. Despite having downsized, Osmotica is still incurring significant and growing ongoing expenses. Running UPNEEQ as a standalone business is challenging and may be doomed to failure. Before deciding on UPNEEQ's investment merits, consider its forthcoming launch into the ocular aesthetics market.

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

OSMTUS PharmaceuticalsUS Market
7D-1.7%-1.9%-0.5%
1Y-74.0%9.0%13.7%

Return vs Industry: OSMT underperformed the US Pharmaceuticals industry which returned 9% over the past year.

Return vs Market: OSMT underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is OSMT's price volatile compared to industry and market?
OSMT volatility
OSMT Average Weekly Movement11.2%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: OSMT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: OSMT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a302Brian Markisonhttps://www.osmotica.com

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company’s promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women’s health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.

Osmotica Pharmaceuticals Fundamentals Summary

How do Osmotica Pharmaceuticals's earnings and revenue compare to its market cap?
OSMT fundamental statistics
Market CapUS$94.12m
Earnings (TTM)-US$105.54m
Revenue (TTM)US$165.90m

0.6x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OSMT income statement (TTM)
RevenueUS$165.90m
Cost of RevenueUS$75.22m
Gross ProfitUS$90.68m
ExpensesUS$196.22m
Earnings-US$105.54m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.27
Gross Margin54.66%
Net Profit Margin-63.62%
Debt/Equity Ratio54.7%

How did OSMT perform over the long term?

See historical performance and comparison

Valuation

Is Osmotica Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OSMT ($1.13) is trading below our estimate of fair value ($54.13)

Significantly Below Fair Value: OSMT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OSMT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: OSMT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSMT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OSMT is good value based on its PB Ratio (1.7x) compared to the US Pharmaceuticals industry average (2.3x).


Future Growth

How is Osmotica Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

58.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSMT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: OSMT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OSMT's is expected to become profitable in the next 3 years.

Revenue vs Market: OSMT's revenue (35.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: OSMT's revenue (35.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OSMT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Osmotica Pharmaceuticals performed over the past 5 years?

-17.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSMT is currently unprofitable.

Growing Profit Margin: OSMT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OSMT is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare OSMT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSMT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: OSMT has a negative Return on Equity (-192.77%), as it is currently unprofitable.


Financial Health

How is Osmotica Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: OSMT's short term assets ($23.4M) do not cover its short term liabilities ($53.9M).

Long Term Liabilities: OSMT's short term assets ($23.4M) exceed its long term liabilities ($867.0K).


Debt to Equity History and Analysis

Debt Level: OSMT's net debt to equity ratio (39.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if OSMT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSMT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OSMT has less than a year of cash runway if free cash flow continues to grow at historical rates of 35% each year.


Dividend

What is Osmotica Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSMT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSMT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSMT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Brian Markison (62 yo)

6yrs

Tenure

US$3,833,853

Compensation

Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison has been an Operating Executive and Healthcare Industry Execu...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD3.83M) is above average for companies of similar size in the US market ($USD578.13K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OSMT's management team is seasoned and experienced (6 years average tenure).


Board Members

Experienced Board: OSMT's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OSMT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.1%.


Top Shareholders

Company Information

Osmotica Pharmaceuticals plc's employee growth, exchange listings and data sources


Key Information

  • Name: Osmotica Pharmaceuticals plc
  • Ticker: OSMT
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$94.118m
  • Shares outstanding: 83.29m
  • Website: https://www.osmotica.com

Number of Employees


Location

  • Osmotica Pharmaceuticals plc
  • 400 Crossing Boulevard
  • Bridgewater
  • New Jersey
  • 8807
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/17 23:31
End of Day Share Price2022/01/14 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.